Understanding Immunity to the Flu Vaccine in COVID-19 Patients
Study Details
Study Description
Brief Summary
The purpose of this study is to measure immunity to the flu vaccine over time in patients who had COVID-19. Adults who have been diagnosed with COVID-19 as well as controls without COVID-19 will be invited to participate in this study.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
COVID-19 participants
|
Biological: Flu shot
All participants will receive a single shot of the flu vaccine
|
Control participants
|
Biological: Flu shot
All participants will receive a single shot of the flu vaccine
|
Outcome Measures
Primary Outcome Measures
- Testing immunity to the flu vaccine over time [2 months]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Adults enrolled in study 55689 (NCT04373148)
-
Adults diagnosed with severe or moderate COVID-19 at least 2 months prior enrollment
-
Adults without COVID-19 diagnosis for healthy controls
-
Healthy controls may also be recruited outside of IRB#55689
Exclusion Criteria:
-
Received the influenza vaccine less than 4 months ago
-
Pregnant or lactating
-
Patients with special risks attendant to venipuncture
-
Adults who test positive for COVID-19 (pcr test)
-
Use of immunomodulatory medications
-
Immunodeficiency or autoimmune disease
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Stanford University, Hospital, and Clinics | Stanford | California | United States | 94305 |
Sponsors and Collaborators
- Stanford University
- National Institute of Allergy and Infectious Diseases (NIAID)
Investigators
- Principal Investigator: Kari Nadeau, MD, PhD, Stanford University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- IRB-58356
- 5U19AI057229-17